公开(公告)号：US20200030355A1

公开(公告)日：2020-01-30

申请号：US16248925

申请日：2019-01-16

申请人： Epizyme, Inc. ,  Celgene Corporation

发明人： Christine KLAUS ,  Maria Alejandra RAIMONDI ,  Scott Richard DAIGLE ,  Roy MacFarlane POLLOCK ,  Vivek CHOPRA

IPC分类号： A61K31/7064 ,  A61K45/06 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/4745 ,  A61K31/136 ,  A61K31/704 ,  A61K31/5377 ,  A61K31/4045 ,  A61K31/135 ,  A61P35/00

摘要： The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20210052595A1

公开(公告)日：2021-02-25

申请号：US16060164

申请日：2016-12-07

申请人： Epizyme, Inc.

发明人： Stephen BLAKEMORE ,  Scott Richard DAIGLE

IPC分类号： A61K31/5377 ,  C12Q1/6886

摘要： The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.

公开(公告)号：US20220193084A1

公开(公告)日：2022-06-23

申请号：US17546843

申请日：2021-12-09

申请人： Epizyme, Inc.

发明人： Stephen BLAKEMORE ,  Scott Richard DAIGLE

IPC分类号： A61K31/5377 ,  C12Q1/6886

摘要： The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.

公开(公告)号：US20190216838A1

公开(公告)日：2019-07-18

申请号：US16214783

申请日：2018-12-10

申请人： Epizyme, Inc.

发明人： Edward J. OLHAVA ,  Richard CHESWORTH ,  Kevin W. KUNTZ ,  Victoria M. RICHON ,  Roy M. POLLOCK ,  Scott Richard DAIGLE

IPC分类号： A61K31/7076 ,  A61K31/52

CPC分类号： A61K31/7076 ,  A61K31/52

摘要： The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US20230201212A1

公开(公告)日：2023-06-29

申请号：US16622391

申请日：2018-06-13

申请人： Epizyme, Inc.

发明人： Stephen BLAKEMORE ,  Scott Richard DAIGLE

IPC分类号： A61K31/5377 ,  C12Q1/6886

CPC分类号： A61K31/5377 ,  C12Q1/6886 ,  C12Q2600/156

摘要： The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations, or exhibits a genetic profile, listed in Tables 1-5, and/or FIGS. 1-3.

公开(公告)号：US20210268012A1

公开(公告)日：2021-09-02

申请号：US17140331

申请日：2021-01-04

申请人： Epizyme, Inc.

发明人： Edward J. OLHAVA ,  Richard CHESWORTH ,  Kevin W. KUNTZ ,  Victoria M. RICHON ,  Roy M. POLLOCK ,  Scott Richard DAIGLE

IPC分类号： A61K31/7076 ,  A61K31/52

摘要： The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.